ABSTRACT OBJECTIVES This study aimed to evaluate the cumulative effect of treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure (CPAP) on atrial fibrillation (AF) recurrence.
A ntiarrhythmic drugs and catheter ablation with pulmonary vein isolation (PVI) comprise the mainstay of therapies available to maintain sinus rhythm in patients with atrial fibrillation (AF). Despite being efficacious in the general population, select groups of patients remain resistant to these therapies and continue to have recurrent AF (1, 2) . Patient comorbidities, such as increasing age, hypertension, obesity, and diabetes mellitus, are known risk factors that are associated both with development of new-onset AF and its recurrence (3) .
Aggressive treatment of any of these reversible factors with the goal to reduce the future burden of AF has been promoted; however, there remains a paucity of data to support this hypothesis (4) .
Obstructive sleep apnea (OSA) is one such known risk factor that is associated both with new-onset AF and also with its recurrence after catheter ablation (5, 6) . The effect of continuous positive airway pressure (CPAP) use with the goal of reduction in AF recurrence has been evaluated in a few studies with a suggestion of favorable outcomes. However, these studies are often a single-center experience, with small patient populations and divergent results.
Consequently, there remains a significant need to comprehensively evaluate the available data to develop a consensus on the effect of CPAP use and evaluate any effect on AF recurrence.
Toward this end, we performed a metaanalysis of the available published data to evaluate the effects of the use of CPAP therapy in patients with OSA on AF recurrence.
The prevalence of AF and its associated global impact on health care is expected to rise dramatically in the coming decade.
Despite small, albeit significant, improvements in currently-available treatment modalities, there remains a pressing need to evaluate alternative therapies to control AF. Thus, if the use of CPAP has any potential additive or supplementary benefit to control the progression of AF, this is likely to have large-scale effects on this disease entity and its associated patient morbidity and mortality.
METHODS
SEARCH OF THE PUBLISHED DATA. Two independent reviewers (A.S., A.A.) searched MEDLINE, EMBASE, CINAHL, Google Scholar, Cochrane Database of Systematic Reviews, and Cochrane Trials Register. The search was restricted to studies in human subjects published in scientific journals from 1966 to June 2014. The search terms used were "atrial fibrillation," "recurrence," "obstructive sleep apnea," "continuous positive airway pressure," and "pulmonary vein isolation." The reference list of the retrieved studies, review papers, and other meta-analysis relevant to the topic were evaluated to find other potentiallyeligible studies. Data from unpublished studies that were available as abstracts were not considered in this analysis.
STUDY SELECTION. Inclusion criteria for a retrieved study to be included in the current analysis were: 1) controlled study, either of an observational type or a randomized controlled trial (RCT); 2) study subjects to include patients with diagnosed OSA; 3) study to have evaluated effect of CPAP therapy on AF recurrence; 4) patients with OSA and symptomatic AF referred for index ablation procedure (PVI); 5) outcome reported clinically in terms of AF recurrence; and 6) study duration of more than 6 months. Exclusion criteria were: 1) no data provided for comparison amongst CPAP users and nonusers; and 2) no report of AF recurrence.
Comparison of AF recurrence in CPAP users and nonusers in patients with OSA was the primary outcome evaluated in this study. The secondary outcome was evaluation of AF recurrence in CPAP users and nonusers after PVI.
DATA ABSTRACTION AND QUALITY ASSESSMENT.
The review process was carried out on the basis of the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) group guidelines (7) . The reviewers independently assessed the eligibility of each study for inclusion. Any discrepancy in the inclusion or exclusion of a study or data retrieved was resolved by discussion with a third senior reviewer. The data recorded from the included studies were as follows: year of publication, geographic area for patient population, inclusion and exclusion criteria, baseline characteristics of patients, study duration, any PVI performed, and AF recurrence at study endpoint in 2 groups. The quality of each included study was evaluated using the Newcastle-Ottawa scale (8 (10) and Orwin (11) .
A subgroup analysis was performed to evaluate the influence of CPAP use on AF recurrence in patients that did or did not undergo PVI. A sensitivity analysis was performed to ascertain whether the summary estimate of the effect was significantly affected by a single study. Toward this end, pooled estimates were recalculated, using a random-effects model, by excluding one study at a time.
Univariate meta-regression analyses were performed to evaluate patient and study covariates as Shukla et al. 
RESULTS
STUDY SELECTION. The search of the published data yielded a total of 452 citations, of which 445 were excluded ( Figure 1 ). Seven studies with a prospective cohort design met the pre-specified inclusion and exclusion criteria (13) (14) (15) (16) (17) (18) (19) . In 5 of these studies, the patients underwent catheter ablation of AF with PVI, and the risk for AF recurrence was compared between CPAP users and nonusers (PVI group) (14, 15, (17) (18) (19) .
In 2 studies, patients were managed medically, including the use of antiarrhythmic drugs, and AF recurrence was compared among CPAP users and nonusers (non-PVI group) (13, 16) . One of these studies enrolled patients that underwent cavotricuspid isthmus ablation for atrial flutter, and this study was included in the non-PVI group by consensus (16).
STUDY CHARACTERISTICS AND QUALITY. Table 1 with OSA on the basis of polysomnography. In all but 2 studies (Naruse et al. [18] and Bazan et al.
[16]), diagnosis of OSA and consequent use of CPAP was initiated before enrollment into the respective studies. Additional polysomnography criteria used for diagnosis was detailed in 5 of these studies (15) (16) (17) (18) (19) . Adherence to use of CPAP was documented on the basis of patient report on follow-up visits in all studies except in the study by Naruse et al. (18) . In this study, a modem connected to the CPAP facilitated the downloading of information to a central computer that yielded individual objective adherence data ( Table 2 ). Quality of all included studies was high on the basis of Newcastle Ottawa scale ( Table 3) .
Electrocardiographic documentation of AF remained the mainstay for evaluation of AF recurrence.
In all but 2 studies, recurrent atrial tachyarrhythmia during the study period was also considered as a primary endpoint (14, 16, 18) . The median blanking period post-ablation was 10 weeks (range 2 to 12 weeks). In 4 of 5 studies, the number of ablation procedures that an enrolled patient underwent was CPAP ¼ continuous positive airway pressure; PVI ¼ pulmonary vein isolation. one (13, 14, 17, 18) . In 1 study, repeat ablation was offered upon AF recurrence, but details about the repeat ablation procedures was not available (17) . OUTCOME ANALYSIS. Across 7 studies with a total study population of 1,087, users of CPAP had a sig- The forest plot exhibits effect size of each included study (solid box) with 95% confidence interval (CI) (black lines through solid squares).
The diamond (and broken vertical line) at the bottom represents pooled summary estimate with its CI given by its width. AF ¼ atrial fibrillation;
CPAP ¼ continuous positive airway pressure; OSA ¼ obstructive sleep apnea; RR ¼ relative risk ratio.
Shukla et al. (Table 4) .
DISCUSSION
This pooled analysis of systematically-selected studies presents robust evidence that use of CPAP in patients with OSA is associated with a significant reduction in recurrence of AF. The effect size remains consistent and similar across patient groups irrespective of whether or not the patients underwent PVI or were medically managed. Lack of any significant association between patient and study covariates (known to affect arrhythmia outcomes) and AF recurrence suggests that CPAP use may be primarily responsible for these results and that these findings
are not due to a chance effect. These study findings PVI ¼ pulmonary vein isolation; other abbreviations as in Figure 2 . Tables 1 and 2 . Abbreviations as in Figure 2 . Current AF guidelines recognize that OSA is one of the risk factors for development of AF and that its presence reduces success with ablation (35, 36) .
However, there is no recommendation to screen patients for and treat OSA. Given the 42% relative risk reduction seen in the present study, which may now evolve to be a third major treatment option (in addition to medical therapy and ablation), revision of the current AF guidelines may be in order.
CONCLUSIONS
The use of CPAP is associated with a 42% relative risk reduction in AF recurrence in patients with OSA.
This reduction of AF recurrence appears to be independent of medical or catheter ablation therapy and is consistent across patient groups with OSA.
These results advocate for active screening for undiagnosed OSA in patients with AF when OSA is clinically suspected. The use of CPAP offers to be the third potential treatment option for AF (in addition to medical therapy and PVI), and although results from RCTs may be warranted to understand the true extent of its efficacy, its use and adherence needs to be promoted aggressively in these patient groups. 
